Why the study?
Data regarding the effect of renin-angiotensin system inhibition on long-term outcomes after PCI versus CABG in patients with left main coronary disease are lacking.
Does ACEI/ARB treatment at discharge modify the comparative long-term outcomes of PCI versus CABG in patients with left main coronary artery disease?
RCT (n=1,905)
randomized
Yes
Does ACEI/ARB treatment at discharge modify the comparative long-term outcomes of PCI versus CABG in patients with left main coronary artery disease?
ACEI/ARB therapy at discharge may mitigate the higher long-term mortality and revascularization risks observed with PCI compared to CABG in patients with left main coronary artery disease.
Supports PCI-CABG equipoise for 5-year survival in ACEI/ARB-treated LMCAD; extends revascularization trial data to guideline-directed medical therapy subgroups.
BACKGROUND: There is a paucity of data regarding the effect of inhibition of the renin-angiotensin system on outcomes after percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). We sought to examine long-term outcomes of patients with left main coronary disease (LMCAD) randomized to PCI with fluoropolymer-based cobalt-chromium everolimus-eluting stents or CABG according to treatment at discharge with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in the large-scale, multicenter, randomized EXCEL trial. METHODS: EXCEL randomized 1905 patients with LMCAD of low and intermediate anatomical complexity (visually-assessed SYNTAX score ≤32) to PCI (n = 948) versus CABG (n = 957). Patients were categorized according to whether they were treated with ACEI/ARB at discharge; their outcomes from discharge to 5 years were examined using multivariable logistic regression with an offset for follow-up time. RESULTS: Among 1775 patients discharged alive with known ACEI/ARB treatment status, 896 (50.5%) were treated with one of these agents. Among those treated with ACEI/ARB, the 5-year rate of all-cause death was similar after PCI or CABG (10.7% versus 9.8% respectively, adjOR, 0.94; 95% CI, 0.56-1.57) in contrast to patients not treated with ACEI/ARB (15.0% versus 7.8%, respectively, adjOR, 2.20; 95% CI, 1.32-3.67) (Pinteraction = 0.02). Significant interactions between treatment arm (PCI versus CABG) and ACEI/ARB treatment status were also found for cardiovascular death (Pinteraction = 0.03), ischemia-driven revascularization (Pinteraction = 0.03), target vessel revascularization (Pinteraction = 0.007) and target vessel failure (Pinteraction = 0.0009). CONCLUSION: In the EXCEL trial, the postdischarge rates of death and revascularization after 5 years were similar after PCI and CABG in patients with LMCAD treated with ACEI/ARB at discharge. In contrast, event rates were higher after PCI versus CABG in those not so treated.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted an RCT in Left main coronary artery disease (LMCAD) (n=1,905). Percutaneous coronary intervention (PCI) vs. Coronary artery bypass grafting (CABG) was evaluated on All-cause death at 5 years (among patients treated with ACEI/ARB) (adjOR 0.94, 95% CI 0.56-1.57).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: